Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · Headline outcomes only

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 100%Moderate 0 · 0%High 0 · 0%

Number of participants with any serious adverse events · primary progressive multiple sclerosis

Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Ocrelizumab for multiple sclerosis 2022 · Cochrane Headline outcomes only
RR 0.92 [0.68, 1.23]
1 study · 725 participants
Low

Number of participants with any serious adverse events · patients with relapsing‐remitting multiple sclerosis

Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Ocrelizumab for multiple sclerosis 2022 · Cochrane Headline outcomes only
RR 0.79 [0.57, 1.11]
2 studies · 1651 participants
Low